Synpromics to operate as a wholly owned subsidiary; the two companies bring together pioneering technology to increase efficacy of gene therapeutics
Category: News
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s IndustryLeading Gene Therapy Platform in Strategic Partnership
Development pipeline and human trials planned for repeat dosing of AAV-based gene therapies to address the unmet medical need for patients with rare and orphan genetic diseases.
Statement: Pfizer Phase 1b Clinical Trial Results
Pfizer reported results from a Phase 1b clinical trial of PF-06939926, its investigational gene therapy for Duchenne Muscular Dystrophy (DMD).
Newly Approved Spinal Muscular Atrophy Gene Therapy, Zolgensma®, Validates AskBio Gene Therapy Platform
AskBio continues to lead the path for gene therapy development and cost-effective manufacturing methods based on the contributions of its co-founder, Dr. Jude Samulski
AskBio Partners with TPG and Vida Ventures
Leading gene therapy company announces $235 million investment to accelerate growth
First Patient Dosed with Gene Therapy in Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease
-Initial clinical study to evaluate ACTUS-101 over 52 weeks that could improve quality of life for those who are affected with rare genetic disorder – Pompe Disease.
Asklepios BioPharmaceutical, Inc. Launches New Portfolio Company – Actus Therapeutics, Inc.
Company will target rare genetic diseases including Pompe Disease
AskBio and Columbus Venture Partners Launch Gene Therapy Company Viralgen
New vector core facility will be located in San Sebastián, Spain
NanoCor Announces New Data on Congestive Heart Failure Gene Therapy
Up to 25 percent improvement in large animal model
Pfizer Aims To Become Industry Leader In Gene Therapy With Acquisition Of Bamboo Therapeutics, Inc.
Acquisition combines Bamboo’s gene therapy portfolio, advanced vector design, and production technologies and capabilities with Pfizer’s global scale, research, development and commercialization experience
